États financiers détaillés de Enliven Therapeutics, Inc. (ELVN): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.
Compte de Résultat (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coût des Ventes | 0 | 0 | $33000 | 0 | 0 | 0 | 0 | 0 | $263000 |
| Marge Brute | 0 | 0 | -$33000 | 0 | 0 | 0 | 0 | 0 | -$263000 |
| R&D | $7.9M | $8.2M | $19.0M | $8.2M | $20.5M | $31.0M | $64.6M | $80.8M | $85.9M |
| Frais Généraux | $987000 | $2.4M | $5.1M | $1.1M | $4.3M | $7.8M | $19.0M | $23.8M | $33.8M |
| Charges Opérationnelles | $8.9M | $10.7M | $24.1M | $9.3M | $24.8M | $38.8M | $83.5M | $104.6M | $119.4M |
| Résultat Opérationnel | -$8.9M | -$10.7M | -$24.1M | -$9.3M | -$24.8M | -$38.8M | -$83.5M | -$104.6M | -$119.7M |
| EBITDA | $221000 | -$11.3M | -$23.4M | -$9.3M | -$24.6M | -$37.4M | -$71.3M | -$88.5M | -$103.4M |
| Charges d'Intérêt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Avant Impôts | $221000 | -$11.3M | -$23.5M | -$19.0M | -$24.7M | -$37.7M | -$71.6M | -$88.8M | -$103.7M |
| Impôts | $221000 | 0 | 0 | 0 | 0 | 0 | 0 | $232000 | 0 |
| Résultat Net | 0 | -$11.3M | -$23.5M | -$19.0M | -$24.7M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
| BPA | $0.00 | $-2.62 | $-5.43 | $-4.31 | $-3.17 | $-6.03 | $-2.01 | $-1.89 | $-1.83 |
| BPA Dilué | $0.00 | $-2.62 | $-5.43 | $-4.31 | $-3.17 | $-6.03 | $-2.01 | $-1.89 | $-1.83 |
| Actions en Circulation (Diluées) | $4.3M | $4.3M | $4.3M | $4.4M | $7.8M | $6.2M | $35.5M | $47.1M | $56.7M |
Bilan (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $9.7M | $7.4M | $4.9M | $47.7M | $110.0M | $75.5M | $100.1M | $124.1M | $98.9M |
| Placements à Court Terme | 0 | 0 | $24.0M | $40.5M | 0 | 0 | $153.0M | $189.3M | $363.7M |
| Créances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $10.2M | $7.7M | $30.6M | $90.4M | $110.7M | $77.8M | $266.2M | $318.1M | $474.9M |
| Immobilisations Corporelles | 0 | 0 | $442000 | $349000 | $954000 | $1.5M | $1.1M | $458000 | $417000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $10.2M | $7.7M | $33.3M | $90.8M | $113.3M | $83.3M | $271.9M | $325.8M | $476.2M |
| Dettes Fournisseurs | $431000 | $908000 | $1.7M | $2.0M | $2.5M | $3.4M | $532000 | $1.3M | $2.2M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Courants | $826000 | $1.8M | $4.2M | $6.2M | $5.8M | $9.7M | $25.9M | $15.9M | $16.6M |
| Dette à Long Terme | $660000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Totaux | $1.5M | $1.8M | $4.4M | $6.4M | $6.5M | $160.1M | $26.0M | $15.9M | $16.7M |
| Réserves | -$20.0M | -$31.3M | -$54.8M | -$96.1M | -$45.2M | -$82.9M | -$154.4M | -$243.5M | -$347.2M |
| Capitaux Propres | -$15.5M | -$26.3M | -$48.8M | $84.4M | $106.9M | -$76.8M | $245.9M | $309.8M | $459.6M |
| Dette Totale | $660000 | 0 | 0 | 0 | $159000 | $323000 | $335000 | 0 | $399000 |
| Dette Nette | -$9.0M | -$7.4M | -$28.9M | -$88.2M | -$109.9M | -$75.2M | -$252.8M | -$313.4M | -$462.2M |
| Fonds de Roulement | $9.4M | $5.9M | $26.4M | $84.2M | $104.9M | $68.0M | $240.3M | $302.2M | $458.3M |
Tableau de Flux (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Résultat Net | 0 | -$11.3M | -$23.5M | -$19.0M | -$24.7M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
| Amortissements | 0 | 0 | $33000 | $45000 | $115000 | $215000 | $297000 | $317000 | $263000 |
| Stock-based Compensation | 0 | $555000 | $899000 | $130000 | $1.9M | $3.2M | $12.9M | $20.2M | $34.0M |
| Variation du BFR | -$188000 | $1.2M | $673000 | $583000 | $3.6M | $438000 | $1.4M | -$4.5M | -$1.1M |
| Cash Flow Opérationnel | -$8.8M | -$8.8M | -$21.9M | -$8.5M | -$19.1M | -$32.1M | -$61.3M | -$73.2M | -$70.3M |
| CapEx | 0 | 0 | -$140000 | -$461000 | -$191000 | -$612000 | -$149000 | -$44000 | -$158000 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | $35.0M | 0 | 0 | 0 |
| Rachat d'Actions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendes Payés | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$8.8M | -$8.8M | -$22.0M | -$9.0M | -$19.3M | -$32.7M | -$61.4M | -$73.2M | -$70.5M |
Croissance et Marges (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Croissance Résultat Net (annuelle) | -107.0% | +19.2% | -30.4% | -52.2% | -90.1% | -24.4% | -16.5% | ||
| Croissance BPA (annuelle) | -107.3% | +20.6% | +26.5% | -90.2% | +66.7% | +6.0% | +3.2% | ||
| Variation Actions (annuelle) | +0.0% | +0.0% | +1.6% | +78.0% | -20.0% | +468.8% | +32.4% | +20.4% | |
| Croissance FCF (annuelle) | +0.1% | -150.8% | +59.2% | -115.0% | -69.2% | -87.9% | -19.2% | +3.8% | |
| Taux d'Imposition Effectif | 100.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.3% | -0.0% |
Données par Action (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| FCF par Action | $-2.03 | $-2.03 | $-5.10 | $-2.05 | $-2.47 | $-5.23 | $-1.73 | $-1.56 | $-1.24 |
| Dividende par Action | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Actions en Circulation (Basiques) | $4.3M | $4.3M | $4.3M | $4.4M | $7.8M | $6.2M | $35.5M | $47.1M | $56.7M |
Quoi regarder en Biotech
La plupart des petites biotechs perdent de l'argent. Les analyser avec le P/E n'a aucun sens — regardez cash et pipeline.
- Cash Runway — Mois de cash au rythme actuel. <18 mois = risque de dilution urgente
- Cash burn annuel — Rythme de consommation de cash opérationnel. À comparer à la position de cash
- Total Debt — Biotech sans revenus + dette = recette de faillite
- R&D / Capitalisation — Combien ils investissent dans le pipeline vs la valeur de l'entreprise — intensité R&D
- Capitalisation / Cash — S'il cote près de son cash, le marché donne ~0 valeur au pipeline — opportunité ou piège
Ratios Clés (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| PER | 0.00 | -22.90 | -11.05 | -20.46 | -2.84 | -2.71 | -6.89 | -11.90 | -8.42 |
| P/B | -16.69 | -9.85 | -5.31 | 4.59 | 0.66 | -1.33 | 2.00 | 3.42 | 1.90 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Marge Brute | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Marge Opérationnelle | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Marge Nette | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Entreprises liées: ATAI · DNTH · IMTX · INBX · NKTR · ORIC · PGEN
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de ELVN: Vue d'ensemble · Valorisation · Statistiques · Estimations · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions